Psoriatic Arthritis

Latest News

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.

Sign Up for Free e-newsletters